The effect of imatinib on cytomegalovirus reactivation in hematopoietic cell transplantation. - Wikidata - awgldk - TriplyDB

The effect of imatinib on cytomegalovirus reactivation in hematopoietic cell transplantation.

The effect of imatinib on cytomegalovirus reactivation in hematopoietic cell transplantation.

http://www.wikidata.org/entity/Q37426727

about

Cytomegalovirus: pathogen, paradigm, and puzzle Dasatinib Use and Risk of Cytomegalovirus Reactivation After Allogeneic Hematopoietic-Cell Transplantation.The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication.

P2860

Q33351523-AEF21997-D7F0-4A90-8945-B81FC460E61C Q40238365-76ACCD4E-8079-4CDD-9943-D741056C77BD Q54413526-0B862D15-3B06-4931-A3D3-6874C20BFB3C

P2860

The effect of imatinib on cytomegalovirus reactivation in hematopoietic cell transplantation.

http://www.wikidata.org/entity/Q37426727

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The effect of imatinib on cyto ...... opoietic cell transplantation.

@en

The effect of imatinib on cyto ...... opoietic cell transplantation.

@nl

type

label

The effect of imatinib on cyto ...... opoietic cell transplantation.

@en

The effect of imatinib on cyto ...... opoietic cell transplantation.

@nl

prefLabel

The effect of imatinib on cyto ...... opoietic cell transplantation.

@en

The effect of imatinib on cyto ...... opoietic cell transplantation.

@nl

P1433

Q37426727-6A9A3993-F6DC-4863-B452-7BA00093E305

P1476

Q37426727-B72D31F4-A204-4CAF-9198-64B28D14B872

P2093

Q37426727-1B6643E5-0DCC-49CC-99A7-E6E6A3346FE9

Q37426727-4953DD95-F8C1-4FB3-9E74-2C94ACE4E900

Q37426727-538E7841-B46D-4D7E-9593-D19240C9223A

Q37426727-C82AFAC4-0C84-4141-A0C0-C6CB3CC4730A

Q37426727-DBC0C9D5-2327-4738-80F5-AA39CC78D1C0

Q37426727-DCC4A89B-8F82-4B3F-A10B-06ACA29216EB

P2860

Q37426727-0800FF7D-0B6C-4B68-A362-70F90347C089

Q37426727-1079C5A9-F69D-4026-9366-9AC761156A14

Q37426727-10EBDB29-6831-4C74-94CF-ED72E1FAA7AC

Q37426727-35421DA2-D75D-42D0-9232-965ED3F422EC

Q37426727-62405AF3-B02A-49C1-A314-328E56B50A24

Q37426727-65B7367B-2E1D-4C51-B9C6-DAD2DD465171

Q37426727-96369A8C-9DF4-48A9-A757-C4C21933AE7C

Q37426727-9C046B3C-3012-4892-A3A0-CB15AB56794C

Q37426727-A4B5D6DD-AA2A-4C9A-B8C9-427E451BD520

Q37426727-AB4E13A4-E11A-4B7D-B9D4-E0B3AADFB36A

P304

Q37426727-A62CE59F-E811-461C-8621-5D0EB4030DAC

P31

Q37426727-045E2C08-8C27-42F7-968C-EB9B5325AE93

P356

Q37426727-139B5CBE-06A6-4EB0-9EE3-238F75B98DD3

P407

Q37426727-9C2BE162-5AE2-40DE-9E12-1D804066C53D

P433

Q37426727-D36F2162-F3EB-492F-B2FC-847EC892789C

P478

Q37426727-815CD546-AACC-4C78-A142-075469935F07

P50

Q37426727-9E550EE1-9EE9-474E-9413-D7F9BBC406C1

P577

Q37426727-EFA8992C-1EF2-45E7-B8ED-7D92CBD400A3

P5875

Q37426727-8F775689-49F6-4637-8FD4-4D424A38C7CC

P698

Q37426727-383F0F50-932A-4345-B49C-C1DE28AC56E6

P921

Q37426727-35446CF3-F51E-4813-9D7C-99F56C6A6A3E

P932

Q37426727-4F37835C-8B1F-4E41-9CEE-112B24AE1B2D

P356

P1433

Clinical Infectious Diseases

P1476

The effect of imatinib on cyto ...... opoietic cell transplantation.

@en

P2093

Giovanna Travi

http://www.w3.org/2001/XMLSchema#string

Hans-Peter Kiem

http://www.w3.org/2001/XMLSchema#string

Hu Xie

http://www.w3.org/2001/XMLSchema#string

Michael J Boeckh

http://www.w3.org/2001/XMLSchema#string

Paul Carpenter

http://www.w3.org/2001/XMLSchema#string

Steven A Pergam

http://www.w3.org/2001/XMLSchema#string

P2860

Definitions of cytomegalovirus infection and disease in transplant recipients

First demonstration of the effectiveness of inhibitors of cellular protein kinases in antiviral therapy.

Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation.

Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection.

Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections.

Herpes zoster complicating imatinib mesylate for gastrointestinal stromal tumour.

Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate.

Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia.

Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.

Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance.

P304

e120-3

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/648120

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38064820

http://www.w3.org/2001/XMLSchema#string

P698

19886798

http://www.w3.org/2001/XMLSchema#string

P921

Cytomegalovirus

P932

2779734

http://www.w3.org/2001/XMLSchema#string